Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 4.42 EUR -1.78% Market Closed
Market Cap: €78m

Vita 34 AG
Selling, General & Administrative

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vita 34 AG
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Vita 34 AG
XETRA:V3V
Selling, General & Administrative
-€33m
CAGR 3-Years
-51%
CAGR 5-Years
-29%
CAGR 10-Years
-16%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Selling, General & Administrative
-€3B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
0%
Fresenius SE & Co KGaA
XETRA:FRE
Selling, General & Administrative
-€2.9B
CAGR 3-Years
2%
CAGR 5-Years
12%
CAGR 10-Years
5%
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Selling, General & Administrative
-HK$209.3m
CAGR 3-Years
-20%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Selling, General & Administrative
-€3B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
0%
No Stocks Found

Vita 34 AG
Glance View

Market Cap
78m EUR
Industry
Health Care

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.

V3V Intrinsic Value
5.38 EUR
Undervaluation 18%
Intrinsic Value
Price €4.42

See Also

What is Vita 34 AG's Selling, General & Administrative?
Selling, General & Administrative
-33m EUR

Based on the financial report for Sep 30, 2024, Vita 34 AG's Selling, General & Administrative amounts to -33m EUR.

What is Vita 34 AG's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-16%

Over the last year, the Selling, General & Administrative growth was 2%. The average annual Selling, General & Administrative growth rates for Vita 34 AG have been -51% over the past three years , -29% over the past five years , and -16% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett